2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
21
Dermatologic
17
Thoracic
13
Genitourinary
6
Sarcoma
5
Head & Neck
4
Gynecologic
3
Other solid neoplasm
2
Lymphoid
2
Breast
2
Plasma cell
1
Endocrine
1
Conditions
Breast Neoplasms
13132
Triple Negative Breast Neoplasms
1149
Neoplasms
749
Ovarian Neoplasms
680
Neoplasm Metastasis
590
Lung Neoplasms
582
Colorectal Neoplasms
580
Prostatic Neoplasms
560
Carcinoma, Non-Small-Cell Lung
535
Pancreatic Neoplasms
380
Melanoma
366
Stomach Neoplasms
350
Colonic Neoplasms
330
Motor Activity
285
Breast Neoplasms, Male
285
Carcinoma, Intraductal, Noninfiltrating
277
Uterine Cervical Neoplasms
267
Head and Neck Neoplasms
266
Endometrial Neoplasms
256
Carcinoma, Renal Cell
216
Sarcoma
203
Urinary Bladder Neoplasms
192
Squamous Cell Carcinoma of Head and Neck
192
Lymphedema
190
Esophageal Neoplasms
189
Breast Carcinoma In Situ
189
Brain Neoplasms
183
Fatigue
166
Carcinoma, Ovarian Epithelial
151
Small Cell Lung Carcinoma
148
Interventions
pembrolizumab
2
spartalizumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Breast
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts
NCT03849469
2023-03-30
DUET-4
Xencor, Inc.
Phase 1
Completed
78 enrolled